Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 1,728 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions
Allodepleted T Cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
2
States / cities
Houston, Texas
Conditions
B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 54 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Biphenotypic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions
MRI and cognitive evaluation, brain MRI study and a brief neuropsychological evaluation
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
2
States / cities
New York, New York
Terminated Phase 1 Interventional Results available

A Study for Patients With Acute Leukemia

NCT01214655
Conditions
Acute Leukemia
Interventions
LY2523355
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Conditions
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
Interventions
CD7.CAR/28zeta CAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
2
States / cities
Houston, Texas
Conditions
Relapsed Pediatric ALL, Relapsed Pediatric AML, Refractory Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Daunorubicin
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Lymphoma, Neutropenia
Interventions
epoetin alfa, filgrastim, recombinant flt3 ligand, recombinant interleukin-3, sargramostim, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
17 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Compliance Monitoring, Health Promotion and Education, Informational Intervention, Media Intervention, Medical Device Usage and Evaluation, Mercaptopurine, Questionnaire Administration, Telephone-Based Intervention, Training and Education
Procedure · Behavioral · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
10 Years to 25 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 20 more
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Oral Mucositis
Interventions
Aloe Vera Mouthwash, Standard of Care
Dietary Supplement · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
3
States / cities
Oak Lawn, Illinois • Park Ridge, Illinois • Milwaukee, Wisconsin
Conditions
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
Interventions
CAT-8015 (Moxetumomab Pasudotox)
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts + 1 more
Conditions
Leukemia, Lymphoblastic, Acute, ALL, Childhood
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 40 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Lymphoid Leukemia
Interventions
Dasatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma
Interventions
ondansetron, survey administration, management of therapy complications
Drug · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Measurement of Ocular Microtremor With the iTremor Device in a Diverse US Cohort

NCT07858214
Conditions
All Conditions, All
Interventions
Not listed
Lead sponsor
Head Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Cambridge, Massachusetts
Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Interventions
cytogenetic analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1984
U.S. locations
137
States / cities
La Jolla, California • Mountain View, California • San Diego, California + 89 more
Conditions
Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, AMG 404, Dexamethasone Premedication
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 2 more
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia, Histiocytosis
Interventions
Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
Drug · Device · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Autologous Anti-CD19 CAR-expressing T Lymphocytes, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Fludarabine, Leukapheresis, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
55 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
forodesine hydrochloride (BCX-1777)
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Denver, Colorado • Chicago, Illinois • Kansas City, Kansas + 3 more
Conditions
Leukemia
Interventions
docetaxel
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
200
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 148 more
Conditions
Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, amifostine trihydrate, carboplatin, paclitaxel
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
CD22CART infusion, Tisagenlecleucel
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 25 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California